Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 20Myeloid 11Thoracic 2Classical hematology 2Other solid neoplasm 1Lymphoid 1Dermatologic 1CNS 1Breast 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 46Radiosurgery 34Cyclophosphamide 28Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16fludarabine 14X-Rays 13Ipilimumab 13Surgical Procedures, Operative 12Lomustine 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11dinutuximab 10trametinib 9abemaciclib 9AZD 6244 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
decitabine and cedazuridine drug combination × CNS × 90 days × Clear all
NCT03922555 2026-04-16

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

Massachusetts General Hospital

Phase 1 Recruiting
18 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡